NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional)

The National Institutes of Health (NIH) is accepting applications for the NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional) under FOA PAR-24-101. This funding opportunity supports multi-site exploratory and confirmatory clinical trials, as well as biomarker validation studies and ancillary studies related to stroke prevention, treatment, and recovery. The goal is to develop and validate interventions and outcome measures that directly contribute to advancing stroke care. Applicants whose proposals are selected will conduct their research within the NIH StrokeNet infrastructure, collaborating with its National Coordinating Center (NCC) for efficient study implementation. The National Data Management Center (NDMC) will provide data management and statistical support, while Regional Coordinating Centers (RCCs) and their clinical sites will assist with recruitment, retention, and protocol execution. Eligible applicants include state, county, and city governments; tribal governments and organizations; public and private institutions of higher education; nonprofits with or without 501(c)(3) status; for-profit organizations, including small businesses; and other eligible entities such as faith-based organizations, Historically Black Colleges and Universities (HBCUs), and regional organizations. Foreign organizations are not eligible to apply, but foreign components of U.S. organizations may be included as part of the research. Applications must address interventions, biomarker validation, or ancillary studies preparatory to clinical trials. Following peer review, the National Institute of Neurological Disorders and Stroke (NINDS) will prioritize highly rated studies for funding within the StrokeNet framework.